MBCT-vision VSS RCT

Sponsor
Guy's and St Thomas' NHS Foundation Trust (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06018103
Collaborator
(none)
60
2
35

Study Details

Study Description

Brief Summary

Visual Snow Syndrome (VSS) is a neurological condition with bran network dysregulation involving the visual pathway. This is a research trial comparing the effect of an 8-week mindfulness-based intervention via a group-learning course, the MBCT-vision programme, to treat Visual Snow Syndrome, compared to people on a standard care (wait-list control). Participants will be randomly allocated to either the Treatment group (MBCT-vision), or the Control group (wait-list control). After a waiting period, people allocated to the Control group will also be offered the MBCT-vision treatment. The primary outcome is to compare the severity of the visual symptoms on a 0 to 10 scale between the two groups.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: MBCT-vision
N/A

Detailed Description

Visual Snow Syndrome (VSS) is a neurological condition where affected people see flickering dots across their whole visual field, & may have other symptoms such as light sensitivity, after-images, trailing of images, & tinnitus. Functional Magnetic Resonance Imaging (fMRI) studies in VSS have shown brain network dysregulation involving the visual pathway. There is currently no evidence-based validated treatment for VSS, therefore the current standard of care is no treatment.

This research trial is to test the treatment of an intensive mindfulness programme, using the Mindfulness Based Cognitive Therapy customised for visual symptoms (MBCT-vision) programme, for people with Visual Snow Syndrome. MBCT-vision is a group learning programme, where people meet once weekly for 8 weeks. During these once weekly sessions, they learn mindfulness practices. The group discussions about the mindfulness practices introduces cognitive behavioural skills. Participants are given daily home practices between these weekly group learning sessions. We completed a study (ClinicalTrials.gov identifier NCT04184726) showing MBCT-vision was a feasible treatment for VSS.

This clinical trial is a 'randomized controlled trial'(RCT), where the effectiveness of a treatment is evaluated by comparison between two groups. We are recruiting people with VSS. Participants will be randomly allocated to one of two groups: one group receives MBCT-visionÍž while another group received standard care only for 5 months. The second group is called a waiting-list control group, whereby after 5 months, they will receive MBCT-vision treatment. The study will be conducted from single centre at a tertiary care hospital and the MBCT-vision is delivered online.

The key outcome of interest is severity of Visual Snow Syndrome on a 0-10 visual analogue scale. Other outcome measures will be collected to understand the effect of MBCT-vision, including quality of life and psychological wellbeing.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Randomized Control Trial of two groups: Treatment (MBCT-vision), or Control (wait-list, standard of care)Randomized Control Trial of two groups: Treatment (MBCT-vision), or Control (wait-list, standard of care)
Masking:
Single (Outcomes Assessor)
Masking Description:
Statistician performing the analysis will be masked. It is not possible to mask the participant nor the investigator due to the nature of the intervention (group learning programme on mindfulness)
Primary Purpose:
Treatment
Official Title:
MBCT-vision to Treat Visual Snow Syndrome: a Randomized Controlled Trial
Anticipated Study Start Date :
Jan 1, 2024
Anticipated Primary Completion Date :
Jul 1, 2025
Anticipated Study Completion Date :
Dec 1, 2026

Arms and Interventions

Arm Intervention/Treatment
Experimental: Treatment

8-week online group learning course of the MBCT-vision programme

Behavioral: MBCT-vision
8-week mindfulness group learning course, using Mindfulness Based Cognitive Therapy customised for visual symptoms (MBCT-vision). Participants meet once weekly only, with daily home practice between sessions.

No Intervention: Control

wait-list control (standard care, no research intervention)

Outcome Measures

Primary Outcome Measures

  1. Severity of visual symptoms of Visual Snow Syndrome on a 0-10 VAS [5 months]

    Severity of VSS visual symptoms

Secondary Outcome Measures

  1. Psychological wellbeing on the World Health Organisation (WHO) wellbeing index scores [5 months]

    WHO-5 wellbeing index

  2. Psychological distress on the Clinical Outcomes in Routine Evaluation (CORE-10) scores [5-months]

    CORE-10 scores

  3. Impact of Visual Snow Syndrome symptoms on daily life on 0-10 scale [5-months]

    VSS impact

  4. Work and Social Adjustment Scale [5-months]

    impact of VSS on work and social function

Eligibility Criteria

Criteria

Ages Eligible for Study:
16 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • People with VSS according to the ICHD-3 criteria; previously diagnosed by a Neurologist, Ophthalmologist or Neuro-Ophthalmologist
Exclusion Criteria:
  • Patients with co-morbid conditions affecting vision

  • Patients with a current severe depressive or psychotic episode as determined by the psychologist

  • Patients with severe difficulties in emotional regulation as determined by the psychologist

  • Patients unable to provide informed consent for participation

  • Patients with insufficient understanding of spoken English (due to need to participate in group discussions)

  • Patients who have previously completed MBCT or similar mindfulness interventions

  • Persons aged <16 or >80 years

An exploratory sub-study on the change in metabolomics will recruit healthy controls, inclusion criteria:

Healthy Control Inclusion Criteria

  • Family or household member of a similar age (+/- 8years) to a participant with VSS recruited into the MBCT-vision VSS RCT study

  • Person with no symptoms of VSS

  • Person who self-declares as fit and well with no current medical conditions including anxiety or migraine

Healthy Control Exclusion Criteria

  • Person unable to provide informed consent

  • Person with other co-morbid medical or psychological conditions

  • Person aged <16 or >80years

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Guy's and St Thomas' NHS Foundation Trust

Investigators

  • Principal Investigator: Sui Wong, MD, Guy's and St Thomas' NHS Foundation Trust

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Guy's and St Thomas' NHS Foundation Trust
ClinicalTrials.gov Identifier:
NCT06018103
Other Study ID Numbers:
  • 328749
First Posted:
Aug 30, 2023
Last Update Posted:
Aug 31, 2023
Last Verified:
Aug 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Guy's and St Thomas' NHS Foundation Trust
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 31, 2023